ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

DOW JONES NEWSWIRES Endo Pharmaceuticals Holdings Inc.'s (ENDP) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition. Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late. First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply. Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant. Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million. Gross margin fell to 47.2% from 58.7%. Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%. Overall branded drug sales were down 3% while generics sales increased 8%. Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
03/28/201515:03:023 Top Stocks for Obamacare Lovers
03/28/201513:08:023 Little-Known Biotechs Working On Potential Blockbusters
03/28/201512:03:025 Freakishly Expensive Cancer Drugs
03/25/201509:03:02Is It Time for GlaxoSmithKline plc to Change Management?
03/24/201508:11:01Is This The Biggest Threat to Isis Pharmaceuticals Stock?
03/23/201517:44:29This Market Could Grow 6250% in 10 Years
03/23/201510:14:03This Market Could Grow 6250% in 10 Years
03/21/201512:04:06Dividend Stocks: 2 to Avoid, 1 to Buy
03/20/201507:56:19Court rejects Amgen's bid to block Neupogen biosimilar
03/20/201507:52:39How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures...
03/19/201518:46:14Judge Denies Amgen's Request to Block Novartis's Biosimilar of...
03/18/201519:18:18How The Rushed Biosimilar Law Is Yielding Go-Slow Launches
03/18/201507:45:27AstraZeneca combo lung disease drug successful in Phase 3 studies
03/17/201517:24:32ADR Shares End Mixed; BHP Billiton Shares Rise
03/17/201507:35:19New indication for Novartis bone marrow disorder drug cleared...
03/17/201504:45:54Novartis Gets EU Approval for Jakavi Rare Blood Cancer Drug
03/13/201515:51:14Oxford Biomedica Hails Novartis Contract, Narrows Loss
03/13/201506:30:41Wall Street Breakfast: Japan Marches Higher As Nikkei Breaches...
03/12/201516:33:14GSK Plans Partial Stake Sale in Aspen Pharmacare
03/12/201516:32:28GSK Plans to Sell About Half Its 12.4% Stake in Aspen Pharmacare...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad